Another blow to Alzheimer’s field as two drugs fail in study of early-onset disease
Lilly and Roche said that the Phase II/III DIAN-TU trial of their amyloid beta-targeting drugs - gantenerumab and solanezumab - failed to meet its primary endpoint in patients genetically predisposed to early-onset Alzheimer's disease.